A 2024 report from the World Economic Forum and McKinsey Health Institute found that women spend about 25% more of their lives in poor health than men. The same report estimated that closing the women’s health gap could add $1 trillion a year to the global economy by 2040. Women were largely excluded from clinical trials in the United States until the 1990s, and the effects of that history still show in drug dosing, diagnostic criteria and research priorities.
Outcomes make the gap concrete. The CDC reported a US maternal mortality rate of 18.6 deaths per 100,000 live births in 2023, and a large majority of pregnancy-related deaths are considered preventable. About 1.3 million US women reach menopause each year, yet many clinicians receive limited training in managing it. Heart disease, the leading cause of death for women, often goes unrecognized because symptoms differ from the textbook presentation.
Femtech is the industry that has grown around these unmet needs. The term covers apps, devices, diagnostics, clinical services and benefit platforms designed around women’s health. It spans fertility, pregnancy, postpartum care, menstrual health, menopause, pelvic floor health, breast health and more. Women’s health needs are diverse and cannot be reduced to reproductive health alone.
What Is Femtech and Why Does It Matter?
Femtech refers to technology products and services focused on women’s health, a term coined by entrepreneur Ida Tin, founder of Clue. It overlaps with the broader field of women’s health technology. Some products are consumer apps with no regulatory review. Others are FDA cleared devices or clinical services staffed by licensed professionals.
Historical gaps drive demand. Research funding for conditions that mainly affect women has lagged. Diagnoses can take years, as with endometriosis, where delays of seven to ten years are commonly reported. Sex specific data are limited for many conditions, which complicates algorithms trained on male dominated datasets. Access barriers include cost, geography, stigma and a shortage of obstetric and gynecologic care in many rural areas.
Technology can help in several ways. It can bring education and triage to people without nearby clinics, support longitudinal tracking, create new diagnostics and give clinicians structured data. Digital tools do not repair workforce shortages or fix underinvestment in research.
Main Segments of the Femtech Industry
The main segments are fertility, menstrual health, pregnancy, postpartum care, menopause, pelvic health, breast health, diagnostics and digital care delivery. Fertility includes ovulation tracking, hormone monitors and clinics. Pregnancy and postpartum products include remote monitoring, education and support. Menopause is a rapidly expanding segment. Diagnostics range from home tests to imaging and laboratory assays.
Femtech, Personalized Medicine and Health Equity
Equity affects performance. Algorithms trained mostly on white, regularly cycling users may perform worse for people with irregular cycles, polycystic ovary syndrome, or different ancestry. Medical devices such as pulse oximeters have shown accuracy differences across skin tones, which illustrates the problem more broadly. Femtech companies should test across diverse groups.
Affordability and cultural relevance matter. A premium device is out of reach for many people. Culturally relevant content and multilingual support improve access. Underserved populations, including rural patients, people of color and low income families, face the highest burdens, and products should be validated in those groups.
20 Femtech Companies Advancing Women’s Healthcare
Companies were selected for documented products and a clear women’s health focus. The original shortlist included Elektrofi, a drug formulation company that is not a femtech business, which was replaced with Evvy. Corporate situations change often in this sector, so ownership, financial health and product availability should be confirmed. Several companies are not direct care providers, and the profiles say so.
Femtech companies fall into different categories with different evidence and regulatory expectations: clinical services staffed by licensed professionals, benefit managers that coordinate care, consumer apps, home testing devices, wearable devices and large diagnostic and imaging manufacturers. Each profile states which category applies. Wellness tracking is not regulated like a medical device, and only some products have clearance or authorization for a specific claim, which should not be extended to other uses. Reproductive and health data are sensitive, and most consumer apps are not covered by HIPAA. Funding and valuation figures reflect investor expectations and are not evidence of clinical benefit. Scenarios labeled hypothetical illustrate use and are not documented cases. Company status changes quickly in this sector, so ownership and product availability should be confirmed.
Digital care and clinical services
1. Maven Clinic
Category: virtual clinic and benefit.
Site: mavenclinic.com
Maven, founded in 2014 by Kate Ryder, provides virtual care for fertility, pregnancy, postpartum, parenting, pediatrics and menopause through clinicians, coaches and navigators, sold mainly to employers and health plans. It reached a valuation of about $1.7 billion in a 2022 funding round. Its model lets employees reach obstetric, mental health and lactation support by video and messaging, with return to work support after leave.
A hypothetical employee pregnant with her first child uses Maven for a mental health appointment and lactation guidance after birth, while her obstetrician handles examinations. Strengths include breadth across life stages and employer reach. Limits include that coverage depends on an employer or plan, care must be coordinated with in person services and published outcome studies on cost and outcomes are largely company authored.
2. Midi Health
Category: clinical care for perimenopause and menopause.
Site: joinmidi.com
Midi Health, founded in 2021 by Joanna Strober, provides virtual and some in person care for women in midlife, with clinicians who evaluate symptoms, order tests and prescribe treatments, including menopausal hormone therapy when appropriate. It has raised venture funding in several rounds and accepts some insurance, which distinguishes it from cash only clinics.
A hypothetical 51 year old with hot flashes, sleep loss and mood changes books a video visit, reviews risks and benefits of hormone therapy and starts treatment with follow up. Menopause care is under served in many primary care settings, and the company fills that gap. Limits include state availability, insurance variation and the need for in person exams or imaging for some concerns. Clinical outcomes data are limited to company reports.
3. Tia
Category: women’s health clinics with virtual care.
Site: asktia.com
Tia, founded in 2017 by Carolyn Witte, runs women’s health clinics in a few US cities that combine in person and virtual primary and gynecologic care, including contraception, sexual health, mental health and wellness services, in a membership and insurance model. Its distinguishing approach is whole person care in a setting built for women.
A hypothetical patient sees a clinician for an annual exam, a mental health visit and a contraception consultation in one place. Strengths include integrated services. Limits include limited geographic reach, the effect of membership fees on affordability and the need to confirm current operating status and insurance participation, since digital health companies change quickly.
4. Kindbody
Category: fertility and family building clinics.
Site: kindbody.com
Kindbody, founded in 2018 by Gina Bartasi, operates fertility clinics offering egg freezing, IVF, intrauterine insemination and gynecologic care, with a model of smaller clinics and employer partnerships. It faced financial and operational challenges in recent years, so its current structure should be confirmed. Fertility clinics report live birth rates to national registries, such as the CDC and SART databases, which patients can use to compare outcomes.
A hypothetical patient considering egg freezing consults a physician, completes testing and a stimulation cycle and stores eggs. Strengths include a modern patient experience and employer access. Limits include cost, uncertain success for any one patient and clinic level variation in outcomes. Patients should review registry data and ask about all fees.
5. Carrot Fertility
Category: benefit management for fertility and family building.
Site: get-carrot.com
Carrot, founded in 2016 by Tammy Sun, administers fertility, adoption, surrogacy, pregnancy and menopause related benefits for employers, with care navigation and a clinic network or reimbursement. It stresses inclusive access for single parents and LGBTQ families and operates across multiple countries.
A hypothetical employee uses Carrot to find a clinic, get cost estimates and track reimbursement under a lifetime benefit maximum. Strengths include global coverage and inclusive design. Limits include that benefit caps may not cover multiple IVF cycles, that employers choose coverage levels and that Carrot does not provide care itself.
Apps and consumer digital products
6. Flo Health
Category: consumer cycle tracking and health app.
Site: flo.health
Flo, operated from London, is among the most used cycle apps, with period predictions, symptom logging, a pregnancy mode, educational content and, in newer versions, an AI health assistant. It reached unicorn status in a 2024 funding round. In 2021 it settled with the Federal Trade Commission over sharing health data with outside parties, and it later introduced an anonymous mode.
A hypothetical user with irregular cycles logs symptoms for several months and brings the record to a clinician. The app’s predictions are estimates and not clinical measurements. Strengths are reach and education. Limits include privacy history, the uncertainty of predictions for irregular cycles and the fact that it does not diagnose conditions.
7. Clue
Category: consumer cycle tracking app.
Site: helloclue.com
Clue, from Berlin, offers cycle tracking and education, with a paid tier, and has collaborated with academic researchers. It operates under European data protection law. Its founder, Ida Tin, popularized the term femtech.
A hypothetical user tracks pain and bleeding across cycles to prepare for a gynecology visit about possible endometriosis. Strengths are a science oriented approach and privacy rights under European law. Limits include fewer clinical services, predictions that rely on regular patterns and the fact that tracking does not establish a diagnosis.
8. Natural Cycles
Category: app with FDA authorized contraceptive claim.
Site: naturalcycles.com
Natural Cycles, from Stockholm, uses daily temperature and an algorithm to identify fertile days. The FDA granted De Novo authorization in 2018 for use as contraception, the first digital contraceptive, and later cleared use with a wearable band. The company reports typical use effectiveness of about 93 percent, lower than most hormonal methods. It also offers modes for pregnancy planning and perimenopause.
A hypothetical user avoiding hormonal methods uses the app and condoms on fertile days. Strengths are regulatory clearance backed by clinical data and a hormone free option. Limits include required daily measurement, lower typical use effectiveness and unsuitability for very irregular cycles.
9. Peanut
Category: social community app.
Site: peanut-app.io
Peanut, founded in London in 2016 by Michelle Kennedy, connects women across fertility, pregnancy, parenting and menopause through matching and group chats. It provides peer support and is not a clinical service.
A hypothetical person going through fertility treatment joins a group to share experiences. Strengths include reduced isolation. Limits include misinformation risk in peer advice, moderation challenges and no clinical oversight. Posts should not replace medical advice.
10. Daye
Category: period and intimate health products with diagnostic ambitions.
Site: yourdaye.com
Daye, founded in London in 2016 by Valentina Milanova, sells period products and has developed a diagnostic tampon concept intended to collect samples for testing for infections and conditions, along with consumer health education. Diagnostic claims require regulatory evidence, so the status of each product should be verified before relying on test results.
A hypothetical user buys period products and uses a home test kit for vaginal health, then discusses results with a clinician. Strengths include attention to under served diagnostics. Limits include limited published validation compared with established laboratory tests and variation of product availability by country. Home results are not a diagnosis.
Home testing and fertility diagnostics
11. Mira
Category: home hormone analyzer.
Site: miracare.com
Mira sells a reusable analyzer and test wands that measure luteinizing hormone and estrogen and progesterone metabolites in urine, with an app that charts values and estimates the fertile window. Quantitative readings give more detail than simple strips.
A hypothetical user with long cycles tests daily around mid cycle to find the surge. Strengths include numeric values. Limits include recurring wand costs, limited independent validation and the need for clinical evaluation for suspected hormonal disorders or prolonged difficulty conceiving.
12. Inito
Category: multi hormone fertility monitor.
Site: inito.com
Inito offers a smartphone attachment that reads strips for luteinizing hormone, an estrogen metabolite and a progesterone metabolite, providing a more complete picture of the cycle than ovulation tests alone. It also introduced a follicle stimulating hormone test.
A hypothetical user sees estrogen rising before the surge and progesterone rising afterward, which suggests ovulation likely occurred. Strengths are multiple hormones in one test. Limits include that most validation comes from company studies and that it is not a substitute for a fertility workup, which includes clinical testing.
13. Evvy
Category: home vaginal microbiome testing with clinician review.
Site: evvy.com
Evvy, founded in 2021 by Priyanka Jain and Krystal Thomas, offers at home vaginal microbiome tests that use DNA sequencing, with reports and clinician access for treatment planning. It addresses recurrent infections such as bacterial vaginosis, which are common and often under diagnosed. It replaces a candidate in the original list that is not a femtech company.
A hypothetical patient with recurrent symptoms mails a sample and reviews results with a clinician. Strengths include attention to an under studied area. Limits include that research on interpreting microbiome results is still developing, that tests are not a replacement for evaluation of symptoms and that insurance coverage may be limited.
14. FertilityIQ
Category: fertility information and clinic comparison. Site: fertilityiq.com
FertilityIQ, founded in 2016 by Deborah and Jake Anderson-Bialis, provides educational content and data from patient and clinician surveys to help people choose clinics and understand treatment. It is an information and data company and not a clinical provider. Ownership has changed in this segment, so current status should be confirmed.
A hypothetical person comparing clinics reviews patient experiences and clinic data. Strengths include transparency in an opaque market. Limits include that survey data can reflect self selected responders and do not replace registry outcomes such as national IVF success rates.
Pregnancy, postpartum and maternal devices
15. HeraMED
Category: home fetal heart rate and maternal monitoring device.
Site: heramed.com
HeraMED, an Israeli company, developed HeraBEAT, a handheld device with an app that records fetal heart rate and maternal measurements at home and shares them with a care team, for use under clinician guidance. Regulatory status varies by market.
A hypothetical clinic gives the device to a patient with a lower risk pregnancy so some check ins occur at home. Strengths include convenience and extra monitoring. Limits include the risk of false reassurance if used without clinical oversight, and the need for clear instructions to call a clinician or go to a hospital for reduced fetal movement.
16. Elvie
Category: wearable breast pumps and pelvic floor trainers.
Site: elvie.com
Elvie, a London company, is known for a quiet wearable breast pump and a pelvic floor trainer with an app. It has reported financial difficulties, including administration proceedings in 2025, so product availability, support and ownership need verification. Pelvic floor training is a recognized first line treatment for some forms of urinary incontinence, and device based biofeedback can aid adherence.
A hypothetical postpartum patient uses a trainer to follow a guided exercise routine. Strengths include design and an app that provides feedback. Limits include company uncertainty and the fact that evidence for specific devices varies, so a pelvic health physical therapist can evaluate persistent symptoms.
17. Willow Innovations
Category: wearable breast pumps.
Site: onewillow.com
Willow, based in San Jose, makes wearable breast pumps that fit inside a bra, sold directly and through insurance supply channels. In the United States, health plans must cover breast pumps under the Affordable Care Act, though coverage rules and brands vary.
A hypothetical working parent uses a wearable pump during meetings and tracks milk volume in an app. Strengths include portability. Limits include cost and cleaning, and that wearable pumps may extract less milk for some users than hospital grade pumps. Lactation consultants can help with supply issues.
Diagnostics, imaging and large medical technology companies
18. Hologic
Category: women’s health diagnostics and imaging manufacturer.
Site: hologic.com
Hologic, based in Marlborough, Massachusetts, is a major women’s health company with breast imaging, including 3D mammography tomosynthesis approved by the FDA in 2011, molecular diagnostics such as Aptima assays for HPV and sexually transmitted infections, and surgical products. It reported about $4.0 billion in revenue for fiscal 2024. In late 2025 it agreed to a take private transaction with Blackstone and TPG, so ownership may have changed.
A hypothetical screening program uses tomosynthesis with an AI assisted reading tool, and a laboratory runs HPV tests as part of cervical screening. Strengths are clinical evidence in screening and scale. Limits include its role as an established medical technology manufacturer and not a consumer startup, and that tomosynthesis can lead to callbacks and false positives.
19. GE HealthCare Women’s Health
Category: division of a large medical technology company.
Site: gehealthcare.com
GE HealthCare provides breast imaging systems, such as its Senographe mammography line, and the Voluson ultrasound family widely used in obstetrics and gynecology, plus related software. Women’s health is one part of a broad imaging portfolio and not a start up.
A hypothetical obstetric clinic uses Voluson ultrasound with automated measurement tools for fetal biometry. Strengths include imaging scale and service networks. Limits include high equipment cost and unequal access in lower resource settings, and AI features in imaging should be evaluated for performance across populations.
20. Roche Diagnostics
Category: clinical laboratory diagnostics manufacturer.
Site: diagnostics.roche.com
Roche Diagnostics sells laboratory tests and analyzers. Its Elecsys sFlt-1 to PlGF ratio test received FDA clearance in 2023 to help assess the risk of progression to preeclampsia with severe features within two weeks in hospitalized pregnant patients with hypertensive disorders at certain gestational ages. A published study, the PROGNOSIS trial in the New England Journal of Medicine in 2016, found that a low ratio ruled out preeclampsia in the following week with a negative predictive value of about 99 percent.
A hypothetical hospital uses the test to decide whether a patient with high blood pressure at 30 weeks can be managed without immediate admission. Strengths include solid clinical evidence for a specific use. Limits include that it is a laboratory test for clinicians and not for consumers, with a defined indication, and that clinical judgment remains central.
| Company | Headquarters | Health segment | Product or service | Delivery model | Geographic reach |
|---|---|---|---|---|---|
| Maven Clinic | New York | Family health | Virtual clinic | Employer, plan access | US, global employers |
| Midi Health | California | Menopause | Clinical care | Virtual, in person | US states |
| Tia | New York | Primary and gynecologic | Clinics | Membership, insurance | US cities, virtual |
| Kindbody | New York | Fertility | Clinics | Self pay, benefits | US |
| Carrot Fertility | California | Fertility benefits | Navigation, network | Employer | Global employers |
| Flo Health | UK | Cycle and pregnancy | App | Subscription | Global |
| Clue | Germany | Cycle tracking | App | Subscription | Global |
| Natural Cycles | Sweden | Contraception, fertility | App, regulated claim | Subscription | Multiple markets |
| Peanut | UK, US | Community | App | Free, premium | Global |
| Daye | UK | Period and intimate health | Products | Direct to consumer | UK, Europe |
| Mira | California | Fertility | Hormone analyzer | Direct to consumer | US, other markets |
| Inito | Massachusetts | Fertility | Hormone monitor | Direct to consumer | US |
| Evvy | New York | Vaginal health | Home test | Direct to consumer | US |
| FertilityIQ | New York | Fertility information | Data resource | Education | US |
| HeraMED | Israel | Pregnancy | Fetal monitor | Clinician supervised | Selected markets |
| Elvie | UK | Postpartum | Pumps, trainers | Direct to consumer | UK, US |
| Willow | California | Postpartum | Breast pumps | Direct to consumer, insurance | US |
| Hologic | Massachusetts | Screening, diagnostics | Imaging, assays | Provider sales | Global |
| GE HealthCare | Illinois | Imaging | Ultrasound, mammography | Provider sales | Global |
| Roche Diagnostics | Switzerland | Maternal diagnostics | Laboratory tests | Provider sales | Global |
How Femtech Is Transforming Reproductive and Maternal Health
Femtech covers menstrual tracking, fertility prediction, ovulation monitoring, assisted reproduction support and pregnancy care. Maternal monitoring tools and remote consultations extend contact with clinicians between visits. Postpartum support addresses recovery and mental health, which matter because complications and depression occur after birth.
Three categories need to be kept apart. Wellness tracking records data and offers general insights without regulatory review. Fertility awareness uses body signals to estimate fertile days and is a recognized method with variable effectiveness. Regulated contraceptive technologies, such as Natural Cycles, hold specific authorization based on clinical data.
Disparities are large. In the US, Black women face maternal mortality rates several times those of white women, according to CDC data. Access to prenatal and reproductive care varies by region and income. Technology that does not address cost, transportation and trust will have limited effect on these gaps.
Fertility and Reproductive Technology
At-home hormone tests, fertility monitors and educational platforms are growing. They can give people more information about their cycles and bring them to clinical care earlier. Prediction algorithms depend on regular cycles and consistent data, and they perform less reliably in irregular cycles, postpartum or perimenopause. A person who has been trying to conceive for 12 months, or 6 months if over 35, should seek clinical evaluation, and the home device should not delay that.
Pregnancy and Postpartum Innovation
Remote blood pressure monitoring, home fetal heart rate devices, educational apps and virtual postpartum care aim to extend support. Clinical oversight is essential. A device that detects an abnormal reading must trigger a clear escalation path to a clinician. Postpartum hypertension and depression are common reasons for emergency visits, and remote programs designed around them have shown promise in pilots, though larger trials are needed.
| Life stage | Healthcare need | Technology application | Intended benefit | Clinical limitations |
|---|---|---|---|---|
| Menstrual years | Cycle understanding | Tracking apps | Awareness, better visit prep | Not diagnostic |
| Trying to conceive | Timing, evaluation | Hormone monitors, clinics | Better timing, earlier referral | Algorithm uncertainty |
| Pregnancy | Monitoring, education | Remote monitoring, apps | Earlier escalation | Not a substitute for prenatal care |
| Postpartum | Recovery, mental health | Virtual care, pumps | Support, access | Needs clinician follow-up |
| Perimenopause and menopause | Symptom management | Telehealth, tracking | Access to treatment | Evidence varies by tool |
| Later life | Heart and bone health | Wearables, screening | Early detection | Limited sex specific data |
Femtech Beyond Reproductive Health
Menopause management is a fast growing area, with telehealth clinics, symptom trackers and hormone therapy access. Cardiovascular health in women is underdiagnosed, and research on sex specific presentation is expanding. Pelvic floor care uses wearable trainers and physical therapy programs. Breast diagnostics rely on mammography and ultrasound, with AI tools in development. Women’s mental health, including perinatal mood disorders, is a priority.
Gaps in research, diagnosis and treatment remain. Many conditions that mainly affect women, such as endometriosis, polycystic ovary syndrome and autoimmune disease, take years to diagnose. Technologies can support women across life stages, but investment has been uneven.
AI, Diagnostics and Personalized Women’s Healthcare
AI supports risk assessment, image interpretation, hormone tracking and coaching. AI tools in breast imaging have shown promise in large European screening studies, and several imaging companies provide cleared products. Wearable data and electronic records may support longitudinal care, such as tracking cycle changes alongside blood pressure or sleep.
Sex specific data and algorithmic bias are key concerns. Models trained on male dominated datasets may misclassify women. Clinical validation across diverse populations is needed, and transparency about training data helps clinicians assess reliability.
| Technology | Application | Validation evidence | Regulatory status | Known limitations |
|---|---|---|---|---|
| Temperature-based contraceptive app | Fertility awareness | Prospective studies | FDA authorized (Natural Cycles) | Typical use failure rates |
| Home hormone analyzers | Ovulation timing | Company studies, limited independent data | Varies | Accuracy depends on use |
| 3D mammography | Breast cancer screening | Large trials | FDA approved | Callbacks, density issues |
| Preeclampsia biomarker test | Risk assessment | Clinical studies | FDA cleared for specific use | Hospital setting |
| Home fetal heart monitors | Remote monitoring | Pilot data | Varies | Not for self diagnosis |
| Cycle tracking apps | Prediction | Mixed | Mostly not regulated | Irregular cycles |
Femtech Investment, Market Development and Commercial Models
Venture capital, research grants and corporate partnerships fund the industry. Estimates of market size and funding vary widely by definition, so headline numbers should be read with attention to methods. Business models include direct to consumer, provider based, insurance supported and business to business. Employers and health plans are major payers for fertility, maternity and menopause benefits.
| Company example | Business model | Payment structure | Insurance integration | Target population | Accessibility considerations |
|---|---|---|---|---|---|
| Maven Clinic | Business to business | Employer pays | Via employer or plan | Employees and dependents | Depends on employer |
| Midi Health | Clinical care | Insurance and self pay | Partial | Midlife women | Insurance coverage varies |
| Flo Health | Direct to consumer | Subscription | None | General users | Free tier available |
| Natural Cycles | Direct to consumer | Subscription | None | Contraception or conception | Cost, regulated markets |
| Willow | Direct to consumer, insurance | Purchase or insurance | Partial | Postpartum people | Coverage depends on plan |
| Hologic | Provider sales | Institutional purchase | Through screening coverage | Screened patients | Facility availability |
Commercial sustainability needs clinical evidence. Employers and plans increasingly ask for outcomes data, and companies without it may struggle. The availability of validated products also depends on research funding, which has historically been limited for women’s health.
Barriers to Femtech Adoption
Barriers include regulatory complexity, privacy concerns, limited clinical validation, affordability and unequal digital access. Regulation can be unclear for products that straddle wellness and medical claims. Reproductive data are especially sensitive, and consent and potential misuse are major concerns, particularly in places where reproductive care is restricted. Many apps are not covered by HIPAA, and enforcement actions have addressed improper data sharing.
Clinician integration is weak. Apps rarely connect to electronic records, so data stay in silos. Fragmented care can leave patients juggling several platforms. Research underrepresentation limits what can be validated. Addressing these barriers requires both better regulation and better product design.
The Future of Femtech
Personalized diagnostics, AI supported women’s health, menopause services, remote maternal monitoring and sex specific medical research are likely focus areas. Better longitudinal data and more inclusive clinical trials would help. Integration with primary care and health systems could make digital tools complementary instead of fragmenting.
Uncertainties include reimbursement, regulation, privacy law and the economics of consumer devices. Commercial innovation does not automatically resolve established disparities. Progress depends on evidence, equitable access and responsible handling of sensitive data.
Medical Disclaimer: The content is for general educational purposes and does not replace professional medical advice, diagnosis or treatment. Seek urgent care for severe pregnancy or postpartum symptoms, such as heavy bleeding, severe headache, vision changes, chest pain or thoughts of self-harm. Regulatory status and product availability change, so verify current details with the manufacturer and regulator.
Frequently Asked Questions
Q: What are femtech companies?
A: Femtech companies develop technology and services focused on women’s health, including apps, devices, diagnostics and digital clinics. They cover areas such as fertility, pregnancy, menopause and pelvic health. They vary from consumer apps to regulated medical products.
Q: How is femtech transforming women’s healthcare?
A: Femtech improves access to education, tracking, remote care and new diagnostics, and it draws attention to under researched needs. Benefits depend on quality, validation and access. It does not replace clinical care.
Q: What are the main categories of femtech?
A: Main categories include fertility, menstrual health, pregnancy, postpartum care, menopause, pelvic health, breast health, diagnostics and digital care delivery. Companies may span several categories.
Q: Can femtech improve access to reproductive healthcare?
A: It can help by offering virtual visits, home testing and education, especially where clinics are scarce. It cannot solve cost, transportation or policy barriers on its own. Quality varies.
Q: How does AI support women’s health?
A: AI helps with risk prediction, image interpretation, cycle analysis and coaching. Performance depends on diverse training data and validation. Clinicians should oversee clinical uses.
Q: Are fertility tracking devices medically validated?
A: Some have clinical studies, and Natural Cycles has FDA authorization as a contraceptive. Many trackers and monitors have limited independent validation. Check regulatory status and published evidence.
Q: How do femtech companies protect reproductive health data?
A: Practices vary. Some limit data collection or store data locally, while others have shared data with third parties. Most consumer apps are not covered by HIPAA. Review privacy policies and deletion options.
Q: What are the emerging trends in femtech?
A: Trends include menopause care, remote maternal monitoring, home diagnostics, AI assisted imaging and sex specific research. Employer and plan coverage is expanding. Evidence is still developing for many products.